Publications by authors named "G Soori"
Purpose: MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients with early-stage breast cancer (BC) from the NSABP B-42 trial.
Patients And Methods: MP was tested in 1,866 patients randomly assigned to receive ELT or placebo.
Article Synopsis
- The study examined the Breast Cancer Index (BCI) to predict benefits from extended endocrine therapy (EET) in hormone receptor-positive breast cancer patients participating in the NSABP B-42 trial.
- A total of 2,178 patients were analyzed, finding minimal overall RFI benefit from extended letrozole therapy, with no significant interaction between BCI levels and treatment outcome.
- However, after four years, patients with high BCI (H/I) showed significant benefits from EET, particularly in the HER2-negative subgroup, suggesting BCI's potential as a predictive marker for future studies.
Background: The National Surgical Adjuvant Breast and Bowel Project B-42 trial evaluated extended letrozole therapy (ELT) in postmenopausal breast cancer patients who were disease free after 5 years of aromatase inhibitor (AI)-based therapy. Seven-year results demonstrated a nonstatistically significant trend in disease-free survival (DFS) in favor of ELT. We present 10-year outcome results.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate the effectiveness of induction chemotherapy before trimodality therapy in patients with esophageal or gastroesophageal junction adenocarcinoma, building on previous findings that suggested potential survival benefits.
- In a phase 2 trial involving 28 centers, patients were randomly assigned to receive either induction chemotherapy (Arm A) or none (Arm B) followed by standard treatment, with pathologic complete response (pathCR) as the primary measure of success.
- Results indicated that while the primary endpoint (pathCR) was not improved, patients receiving induction chemotherapy had significantly longer overall survival and disease-free survival, especially those with well/moderately differentiated tumors, prompting further investigation in future trials.
Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
January 2019
Background: The optimal duration of extended therapy with aromatase inhibitors in patients with postmenopausal breast cancer is unknown. In the NSABP B-42 study, we aimed to determine whether extended letrozole treatment improves disease-free survival after 5 years of aromatase inhibitor-based therapy in women with postmenopausal breast cancer.
Methods: This randomised, double-blind, placebo-controlled, phase 3 trial was done in 158 centres in the USA, Canada, and Ireland.